Allos Therapeutics Reports Third Quarter 2001 Financial Results (PR Newswire) ...``Patient accrual for our Phase III randomized study of RSR13 combined with standard whole brain radiation therapy versus standard whole brain radiation therapy alone for the treatment of......The Company is conducting a pivotal Phase III trial for the treatment of metastatic brain tumors with its lead clinical candidate, RSR13.......By increasing tumor oxygenation, RSR13 has the potential to enhance the efficacy of standard radiation therapy... - Oct 18 9:02 AM ET